GLMD · Eocene Ltd.

Summary

On March 5, 2026, Galmed Pharmaceuticals Ltd. held a Special General Meeting of Shareholders where the proposal described in the proxy statement furnished on February 9, 2026, was approved by shareholders with the requisite majority under the Israeli Companies Law.

Key takeaways

• Special General Meeting held on March 5, 2026
• Proposal from February 9, 2026 proxy statement approved
• Approval by requisite majority per Israeli Companies Law, 5759-1999
• Meeting signed by Allen Baharaff, President and CEO